Elan Corporation, plc (ELN)
-NYSE 11.67 
0.08(0.69%) May 17, 4:05PM EDT
| Prev Close: | 11.59 |
|---|
| Open: | 11.56 |
|---|
| Bid: | 11.54 x 200 |
|---|
| Ask: | 11.75 x 100 |
|---|
| 1y Target Est: | 12.56 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 11.48 - 11.68 |
|---|
| 52wk Range: | 9.37 - 14.91 |
|---|
| Volume: | 3,618,571 |
|---|
| Avg Vol (3m): | 5,706,370 |
|---|
| Market Cap: | 5.95B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- This Week in Biotechat Motley Fool(Sat, May 18)
- The Billion Dollar COPD Deal: Who Gains The Most?at Seeking Alpha(Fri, May 17)
- Here's What Super-Investor Seth Klarman Has Been Buyingat Motley Fool(Thu, May 16)
- Elan publishes response document regarding Echo Pharma offertheflyonthewall.com(Wed, May 15)
- Elan Announces Publication of Response DocumentBusiness Wire(Wed, May 15)
- Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracleat Forbes(Wed, May 15)
- After the close: Edwards discovers the value of stock repurchase planat MarketWatch(Tue, May 14)
- Elan in Royalty Deal with THRXZacks(Tue, May 14)
- Spectrum Pharma Reports 1Q LossZacks(Tue, May 14)
- Who Benefits From This Market Moving Biotechnology Partnership?at Motley Fool(Tue, May 14)
- Stocks Decline Despite Positive Sales Data: Market Recapat Wall St. Cheat Sheet(Mon, May 13)
- ADR REPORT-Japanese ADRs rise 1 pct on yen weaknessat Reuters(Mon, May 13)
- Diversifying Royalties at a Hefty Costat Motley Fool(Mon, May 13)
- Theravance, Glaxo, Elan Star In Biotech Soap Operaat Investor's Business Daily(Mon, May 13)
- Blue Chips Declineat The Wall Street Journal(Mon, May 13)
Key Statistics
| Forward P/E (1 yr): | 58.35 |
|---|
| P/S (ttm): | 29,556.41 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.07 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 75.26 |
|---|
Business Summary
Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple ...
View More